iPunose: To determine overall survival, progression-free sur-"vival, rate of voice preservation, and patterns of failure in locoregionally advanced laryngeal cancer treated with induction chemotherapy with or without surgery followed by concomitant chemoradiation.
Introduction
Conventional management approaches to locoregionally advanced laryngeal cancer have included radical surgery and adjuvant radiotherapy for resectable disease and radical radiotherapy for unresectable disease. Treatment outcomes with these approaches have been generally poor: most published series report long-term locoregional failure rates of 30%-70%, distant failure rates of 20%-30%, and survival rates of 20%-60% [1] [2] [3] . With regard to laryngeal preservation with local disease control, radiotherapy alone series have reported rates of roughly 60% for supraglottic and selected glottic cancers and rates of less than 50% for unselected glottic cancers [3, 4] .
Recent developments in improving disease control, survival, and functional outcome in these patients have focused upon combining radiotherapy with chemotherapy [5] . Randomized trials from the Veterans Administration and the EORTC have utilized the approach of neoadjuvant chemotherapy followed by radiotherapy for responding advanced laryngeal and hypopharyngeal cancer patients, respectively, in an effort to avoid radical surgery of the larynx [6, 7] . Other randomized studies from Duke University and France have reported locoregional control and survival benefits for concomitant chemoradiotherapy over radiotherapy alone for advanced head and neck cancer [8, 9] . Still other investigators have chosen to investigate altered fractionation regimens without the addition of chemotherapy [10] .
Phase II trials conducted at the University of Chicago, Northwestern University, and Michael Reese Hospital have employed an approach of induction chemotherapy followed by concomitant chemoradiotherapy. Induction chemotherapy consisting of cisplatin, 5-fluorouracil , leucovorin, and interferon-a2b was administered with the intent to cytoreduce gross disease to permit organ-preserving therapy and eliminate potential distant microscopic disease [11] . Following induction chemotherapy, concomitant chemoradiotherapy consisting of 5-FU, hydroxyurea, and radiotherapy (FHX) is administered with the intention of improving locoregional disease control over that achievable with radiotherapy alone [12] . This comprehensive chemoradiotherapeutic approach attempts to optimize disease control and functional outcome in the management of locoregionally advanced head and neck cancer.
We have previously published the results of two sequential phase II trials at our institutions with the regimen described above. This report focuses on all 32 patients with laryngeal cancer treated on these protocols. The primary endpoints of this study were locoregional and distant control rates, survival, and laryngeal preservation. In selecting laryngeal cancer patients, we were particularly interested in observing our disease-control rate with laryngeal preservation for a group of patients who would otherwise be treated with a total laryngectomy.
Patients and methods
Between June 1990 and August 1993, 166 patients with locoregionally advanced head and neck cancer were enrolled onto two sequential phase II trials through a joint effort involving the University of Chicago, Northwestern University, and Michael Reese Hospital. All 32 patients with laryngeal cancer were selected for analysis of disease control, survival, and larynx preservation and are the subjects of this report. Eligibility criteria have been previously described in detail and are briefly described here [13] , All patients were diagnosed by biopsy with supraglottic, glottic, or subglottic squamous-cell carcinoma. Evaluation by otolaryngology, medical oncology, and radiation oncology; Cancer and Leukemia Group B performance status of 0-2; normal hematologic, renal, and hepatic function; staging evaluation including triple endoscopy and computed tomography; and signed, informed consent were required. Tumor and nodal staging were determined according to the 1988 American Joint Committee for Cancer Staging system. Thirty patients were determined to have stage IV disease, and two patients were determined to have stage III disease.
Treatment plan
The treatment plan has been previously described in detail and is outlined here [13, 14] . Induction chemotherapy consisted of three cycles of cisplatin, 5-FU, leucovorin, and interferon-oc2b (PFL-IFN) administered every 21 days. Cisplatin at 100 mg/m 2 was given intravenously over six hours on day 1 and was followed by 5-FU at 640 mg/m /d given by continuous infusion on days 1-5. Leucovorin was given either at 100 mg by mouth every four hours on days 1-6 or at 300 mg/m 2 /d by continuous infusion on days 1-6. IFN-ot2b at 2 MU/m 2 /d was given subcutaneously starting 2 hours before the start of cisplatin infusion and then repeated every 24 hours for a total of 6 doses. The only difference between the two trials was in the form of leucovorin that was used: the first trial utilized racemic leucovorin, and the second trial utilized L-leucovorin.
Following induction therapy, patients with complete response (CR) proceeded to concomitant chemoradiotherapy. For patients with partial response (PR), total laryngectomy was only performed when conservative surgical approaches could not adequately encompass gross disease. The extent of surgery at the primary site was not uniform and was determined on a case-to-case basis. Patients with N 2 _3 disease at initial presentation usually also underwent modified radical or functional neck dissection. Some patients with advanced regional disease who achieved a CR after induction chemotherapy did not undergo neck surgery. Patients with no response (NR) or progressive disease (PD) underwent radical surgical procedures.
Following induction chemotherapy with or without surgery, concomitant chemoradiotherapy was initiated. Six to eight cycles of daily fractions of radiotherapy at 180-200 cGy were delivered on days 1-5 concurrently with 5-FU and hydroxyurea (FHX). All therapy was discontinued on days 6-14, and cycles were repeated every 14 days. Total radiotherapy doses ranged from 6800 to 7200 cGy to sites of unresected disease, from 6000 to 6600 cGy to sites of resected disease, and from 5000 to 6000 cGy to the regional lymphatics. Chemotherapy dose reductions for toxicity during this portion of the treatment have been previously described [13] .
After all therapy was complete, patients with persistent disease beyond six weeks were evaluated for surgical salvage.
Statistical analysis
Response was assessed at the end of induction therapy and at one month after completion of all therapy by physical, radiographic, and endoscopic evaluations. CR was defined as disappearance of all clinically evident disease, and clinical CR was usually, but not routinely, confirmed pathologically. PR was defined as reduction of all clinically evident disease by ^ 50% without appearance of new lesions. A response < 50% was considered either NR or PD.
All patients have been followed until either recurrence or death. No patient has been lost to followup. Survival and disease control parameters were calculated using Kaplan-Meier actuarial analysis. Overall survival was defined as time from the first day of treatment until death or last date of contact. Progression-free survival was defined as time from the first day of treatment until date of local failure, regional failure, distant failure, or treatment-related death. Patients developing a second primary tumor were not considered to be treatment failures. Time to locoregional failure was defined as time from the first day of treatment until local failure, regional failure, or treatment-related death. Time to distant failure was defined as time from the first day of treatment until either distant failure or treatmentrelated death. Patients dying without evidence of disease recurrence were censored at the time of death in the analyses of progression-free survival, time to locoregional failure, and time to distant failure. Multivariate analysis of potential prognostic factors was performed using Cox's proportional hazards regression.
Results
Thirty-two patients with laryngeal cancer were enrolled onto the study, and follow-up data are available through October 1999. Median follow-up for the entire population is 44.5 months (range 1-93 months), and median follow-up for surviving patients is 63.0 months (range 40-93 months). Patient characteristics are listed in Table 1 . Sixty-three percent of patients had T 4 disease, and fifty-six percent of patients had N 2 _3 disease. Following induction chemotherapy, clinical CR was observed in 59% and clinical PR was observed in 41% of patients. Following completion of all therapy, pathologic CR was observed in 94% of patients, and pathologic PR and PD were observed in one patient each.
Surgical therapy of the primary site consisted of the following: two total laryngectomies, seven supraglottic (16) 2 (6) 30 (94) laryngectomies, and two wide local excisions. The timing of these surgeries was as follows: 10 were performed after induction chemotherapy and prior to chemoradiotherapy, and 1 was performed after chemoradiotherapy. Of the two patients who underwent total laryngectomy, one patient had a PR after induction therapy but with bulky residual disease, and the other patient experienced local disease progression during the concomitant portion of treatment. The remaining 21 patients underwent biopsy alone. Surgical therapy of the neck consisted of neck dissections for 15 patients, and the timing of these neck dissections was as follows: 5 were performed prior to induction chemotherapy, and 10 were performed after induction chemotherapy and prior to chemoradiotherapy. The remaining 17 patients underwent no neck surgery.
Survival
Overall survival for all patients is demonstrated in Figure 1 . Median overall survival was 44.5 months with actuarial rates of 83%, 66%, and 47% at 1, 3, and 5 years, respectively. Seventeen patients have died: four from recurrent or uncontrolled disease, two from treatmentrelated complications, two from a second primary cancer, and nine from intercurrent disease. Both toxic deaths occurred before completion of all therapy (one respiratory failure and one septic death).
Progression-free survival for all patients is demonstrated in Figure 2 . Median progression-free survival was not reached in our length of followup. Actuarial progression-free survival rates of 86%, 78%, and 78% were observed at one, three, and five years, respectively. Time (months) Figure 2 . Progression-free survival probability.
Actuarial progression-free survival with voice preservation was 83%, 75%, and 75% at one, three, and five years, respectively. Crude voice preservation rate with disease control was 88% (28 of 32). Forward stepwise Cox regression analysis was performed to determine factors predictive of overall and progression-free survival. Tested factors included the following: age, gender, laryngeal subsite, differentiation, tumor stage, nodal stage, dose intensity of chemotherapeutic agents used, radiation dose, and delay during radiotherapy. No factor was found to be predictive of either overall survival or progression-free survival. Fiveyear overall and progression-free survival rates according to tumor and nodal stage are listed in Tables 2 and 3 , respectively.
Analysis of failure
Four patients did not ultimately achieve disease control: local or locoregional failure accounted for all of the failures, and no patient experienced distant failure. All four patients who failed had T 4 disease. Median time to locoregional failure was 8.0 months (range 1-30 months). Actuarial rates of locoregional control were 86%, 78%>, Table 2 . Five-year actuarial survival and failure rates according to and 78% observed at one, three, and five years, respectively. No patient was successfully salvaged. Forward stepwise Cox regression analysis was performed to determine factors predictive of locoregional control. Tested factors included tumor stage, nodal stage, dose intensity of chemotherapeutic agents used, and radiation dose. No factor was found to be predictive of locoregional control. Five-year locoregional and distant control rates according to tumor and nodal stage are listed in Tables 2 and 3 , respectively.
Discussion
We report survival, disease control, and functional outcome for a group of locoregionally advanced laryngeal cancer patients treated with induction chemotherapy followed by an attempt at larynx-conserving surgery and then followed by concomitant chemoradiotherapy. Our main intention in the design of this protocol was two-fold. First, intensive chemotherapy was administered at the start of treatment to cytoreduce gross disease in order to permit organ conservation later and to treat potential microscopic distant disease when distant tumor burden is, theoretically, at its smallest and most curable. Second, concomitant chemoradiotherapy was administered to improve local disease control over that achievable with radiotherapy alone.
Results of this treatment plan compare favorably to those reported following traditional treatment consisting of combinations of radical surgery and radiotherapy. With a median follow-up of over five years, we report actuarial rates at five years of 47% for overall survival, 78% for progression-free survival, 78% for locoregional control, 100% for distant control, and 75% for progression-free survival with voice preservation. Series employing either radical surgery and adjuvant radiotherapy or radiotherapy alone generally report distant failure rates of roughly 25% and locoregional failure rates of 50%.
Comparisons with other laryngeal chemoradiotherapy trials are warranted. The randomized Veterans Administration trial followed a protocol by which patients with at least a PR to induction chemotherapy would proceed to consolidative radiotherapy [6] . In that study, 36% of patients randomized to the chemotherapy arm subsequently underwent total laryngectomy (18% after induction chemotherapy and 18% after radiotherapy), which is a higher than the 6% crude rate reported here. Two factors likely contributed to our higher larynx preservation rate. The VA trial did not permit any form of conservative surgery in its protocol -patients either underwent total laryngectomy during initial therapy or consolidative radiotherapy alone. We instead adopted an organ-sparing approach to surgery where total laryngectomy was performed only for patients poorly responding to chemotherapy or at local relapse. Conservative surgery in our patients achieving a PR after induction chemotherapy may have augmented the local control and subsequent larynx preservation rate achieved by consolidative chemoradiotherapy. Also, we employed concomitant chemoradiotherapy with 5-FU, whereas radiotherapy alone was used for consolidation in the VA trial. 5-FU is well-known as a radiosensitizer, and there are a few reports that suggest 5-FU intensification during concomitant therapy may be of benefit [15] . Other phase II single-institution trials following the VA trial model for treatment assignment report larynx preservation rates 30%-50% [16, 17] .
Most radiotherapy schedules cover roughly 7 weeks total treatment time, whereas our schedule is unusual in that the entire course of radiotherapy spans 12-16 weeks. The conventional time-dose concept in radiotherapy dictates that treatment, once started, should be competed as quickly as possible without causing undue toxicity. In both the laboratory and clinic, lower locoregional disease control rates have been associated with treatment delays [18, 19] . Therefore, based on the available literature, patients receiving alternating week treatment may be expected to be at higher risk for local failure than patients treated with a continuous radiotherapy regimen. This time-dose concept, however, is based upon treatment with radiotherapy alone, and chemotherapy may compensate for the increased locoregional failure risk associated with prolonged radiotherapy [20] . The usual time-dose relationship for radiotherapy alone may therefore not be applicable in this situation.
In summary, our regimen of induction chemotherapy followed by concomitant chemoradiation with or without conservative surgery appears to improve the chance for survival with organ preservation and disease control over conventional therapy in patients with locoregionally advanced laryngeal cancer. Currently, we are directing head and neck protocols toward improving upon our locoregional control rates by intensifying the concomitant portion of therapy with hyperfractionated radiotherapy while also addressing the need to reduce toxicity.
